A Study of NX-1607 in Adults With Advanced Malignancies
Recruiting Status:
Recruiting
Age:
18+
A Phase 1a, Dose Escalation, Safety and Tolerability Study of NX-1607, a Casitas B-lineage Lymphoma Proto-oncogene (CBL-B) Inhibitor, in Adults With Advanced Malignancies, With Phase 1b Expansion in Select Tumor Types
'